Sodium-coupled monocarboxylate transporters and their actions in drug delivery

Abstract

Abstract: Sodium-coupled monocarboxylate transporters contain two subtypes:SMCT1 and SMCT2. Both of them have similar substrate specificity, but SMCT1 has higher affinity for substrate than SMCT2.SMCT1 and SMCT2 are expressed in intestine, kidney and retina.They maintain physiological function of the tissues by transporting monocarboxylate cooperately.In this paper, the biological characteristics, substrates and inhibitors, tissue distribution and physiological function, as well as actions in drug delivery of SMCT1 and SMCT2 are reviewed.

Key words: sodium-coupled monocarboxylate transporter, biological characteristics, tissue distribution, physiological function, drug delivery

CLC Number:

R969.1

XU Qiu-xia, WANG Yin, MA Li-yan. Sodium-coupled monocarboxylate transporters and their actions in drug delivery[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(1): 103-109.

References

[1] Halestrap AP, Meredith D.The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond[J]. Pflugers Arch, 2004,447(5):619-628.
[2] 曾军英, 韩雪峰, 谭支良.单羧酸转运蛋白家族及其生物学功能[J]. 生命的化学, 2008, 28(4):404-407.
[3] Coady M, Chang MH, Charron FM, et al. The human tumour suppressor gene SLC5A8 expresses a Na+-monocarboxylate cotransporter[J]. J Phy siol, 2004, 557(3):719-731.
[4] Gopal E, Umapahy NS, Martin PM, et al. Cloning and functional characterization of human SMCT2 (SLC5A12) and expression pattern of the transporter in kidney[J]. Biochim Biophysica Acta, 2007, 1768(11):2690-2697.
[5] Gopal E, Fei YJ, Sugawara M, et al. Expression of slc5a8 in kidney and its role in Na+-coupled transporter of lactate[J]. J Biol Chem, 2004, 279(43):44522-44532.
[6] Coady MJ, Wallendorff B, Bourgeois F, et al. Establishing a definitive stoichiometry for the Na+ monocarboxylate cotransporter SMCT1[J]. Biophy J, 2007, 93(7):2325-2331.
[7] Ganapathy V, Thangaraju M, Gopal E, et al. Sodiumcoupled monocarboxy late transporters in normal tissues and in cancer[J]. AAPS, 2008, 10(1):193-199.
[8] Rodriguez AM, Perron B, Lacroix L, et al. Identification and characterization of a putative human iodide transporter located at the apical membrane of thyrocytes[J]. J Clin EndocrinolMetab, 2002, 87(7):3500-3503.
[9] Paroder V, Spencer SR, Paroder M, et al. Na+ monocarboxylate transport (SMCT)protein expression correlates with survival in colon cancer:molecular characterization of SMCT[J]. PNAS, 2006, 103(19):7270-7275.
[10] Srinivas SR, Gopal E, Zhuang L, et al. Cloning and functional identification of slc5a12 as a sodium-coupled low- affinity transporter for monocarboxylates (SMCT2)[J]. Biochem J, 2005, 392(Pt 3):655-664.
[11] Thangaraju M, Cresci G, Itagaki S, et al. Sodium-coupled transport of the short chain fatty acid butyrate by SLC5A8 and its relevance to colon cancer[J]. J Gastrointest Surg, 2008, 12(10):1773-1781.
[12] Miyauchi S, Gopal E, Fei YJ, et al. Functional identification of SLC5A8, a tumor suppressor down-regulated in colon cancer, as a Na⁺-coupled transporter for shortchain fatty acids[J]. J Biol Chem, 2004, 279(14):13293-13296.
[13] Gopal E, Miyauchi S, Martin PM, et al. Transport of nicotinate and structurally related compounds by human SMCT1 (SLC5A8) and its relevance to drug transport in the mammalian intestinal tract[J]. Pharm Res, 2007, 24(3):575-584.
[14 ] Martin PM, Gopal E, Ananth S, et al. Identity of SMCT1 (SLC5A8) as a neuron-specific Na+-coupled transporter for active uptake of L-lactate and ketone bodies in the brain[J]. J Neurochem, 2006, 98(1):279-288.
[15] Ganapathy V, Gopal E, Miyauchi S, et al. Biological functions of SLC5A8, a candidate tumour suppressor[J]. Biochem Soc Trans, 2005, 33(Pt 1):237-240.
[16] Takebe K, Nio J, Morimatsu M, et al. Histochemical demonstration of a Na+-coupled transporter for short-chain fatty acids(slc5a8) in the intestine and kidney of the mouse[J]. Bio Res, 2005, 26(5):213-221.
[17] Gopal E, Fei YJ, Miyauchi S, et al. Sodium-coupled and electrogenic transport of B-complex vitamin nicotinic acid by slc5a8, a member of the Na glucose co-transporter gene family[J]. Biochem J, 2005, 388(Pt 1):309-316.
[18] Martin PM, Dun Y, Mysona B, et al. Expression of the sodium-coupled monocarboxylate transporters SMCT1 (SLC5A8)and SMCT2 (SLC5A12)in retina[J]. IOVS,2007, 48(7):3356-3363.
[19] Gupta N, Martin PM, Prasad PD, et al. SLC5A8 (SMCT1)-mediated transport of butyrate forms the basis for the tumor suppressive function of the transporter[J]. Life Sci, 2006, 78(21):2419-2425.
[20] Cuff MA, Shirazi-Beechey SP.The importance of butyrate transport to the regulation of gene expression in the colonic epithelium[J]. Biochem Soc Trans, 2004, 32(Pt 6): 1100-1102.
[21] Thangaraju M, Ananth S, Martin PM, et al. c ebpδNull mouse as a model for the double knock-out of slc5a8 and slc5a12 in kidney[J]. J Biol Chem, 2006, 281(37):26769-26773.
[22] Laffel L.Ketone bodies:a review of physiology, pathophy siology and application of monitoring to diabetes[J]. Diabetes Metab Res Rev, 1999, 15(6):412-426.
[23] Allgayer H.mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease[J]. Aliment Pharmacol Ther, 2003, 18(2):10-14.
[24] MacDermott RP.Progress in understanding the mechanisms of action of 5-aminosalicylic acid[J]. Am J Gastroenterol,2000, 95(12):3343-3345.
[25] Gisbert JP, Gomollón F, Maté J, et al. Role of 5-aminosalicylic acid (5-ASA)in treatment of inflammatory bowel disease:a systematic review[J]. Dig Dis Sci, 2002, 47(3):471-488.
[26] Itagaki S, Gopal E, Zhuang L, et al. Interaction of ibuprofen and other structurally related NSAIDs with the sodium-coupled monocarboxylate transporter SMCT1(SLC5A8)[J]. Pharm Res, 2006, 23(6):1209-1216.

[1]	GUO Lu, ZHONG Zhendong, HAN Yicen, SHI Yi, YANG Yong, BIAN Yuan, LIU Xiaoshu, ZHANG Jing, LANG Qin, ZHONG Tian. Effects of different administration methods on the pharmacokinetics and tissue distribution of ribavirin in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 25-32.
[2]	YANG Huan, SHI Yuhong, RAN Haifeng, CHEN Yijin, XU Xiaoyu. Erythropoietin's biological function and source [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 434-443.
[3]	SUN Rensong, ZHANG Jianbin, FANG Jiani, LYU Xia, TANG Zeyao, TIAN Yan. Application of chitosan nanoparticle served as drug delivery system for cancer therapy#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 65-75.
[4]	ZHONG Kailong, WANG Yongsheng, CHEN Fang, YE Yanrong. Exploration and expectation on treatment strategies of central nervous system diseases based on transporters at blood-brain barrier [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 953-960.
[5]	CHEN Aiying, CHENG Min, MIAO Yunping, YE Xiaodi, TIAN Xuejun, ZHENG Gaoli. Pharmacokinetics and tissue distribution characteristics of sunitinib#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(10): 1105-1110.
[6]	LIU Yan, LIU Jiali, JIA Yuanwei, ZHOU Fang, WANG Guangji, ZHANG Jingwei. Advances in the evaluation of intra-tumoral delivery of antitumor drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(10): 1151-1159.
[7]	XING Han, NING Chen, KONG Dexuan, CAI Hui, ZHOU Shiyu, REN Chang, KONG Ying, CHENG Yujie, CHEN Xijing. Tissue distribution and excretion study of GL-V9 in rats, a wogonin derivative with significant antitumor activity [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 889-895.
[8]	WEI Zhaoming，JIANG Wensheng，GAO Yi，ZHANG Juanjuan. Research and potential clinical application of adipose-derived mesenchymal stem cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 116-120.
[9]	YUAN Yawen, LI Yan, YANG Jin. Development and validation of a sensitive LC-MS/MS method for the determination of para-aminosalicylic acid in different tissues in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(3): 272-280.
[10]	LUO Dan, ZHANG Jing-wei, ZHOU Fang, WU Xiao-lan, WANG Guang-ji. Research progress on the PK evaluation of anti-cancer nano-preparation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(2): 205-211.
[11]	YU Wen-ying, ZHANG Liang, CHEN Guo-shen, YE Jin-cui. Research progress in application of multi-component mixtures of enhancers in transdermal drug delivery [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(1): 103-109.
[12]	FANG Ying-ying, ZHENG Gao-li. Research progress of montmorillonite as drug carriers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(8): 956-960.
[13]	LIU Yi-ming, LIN Ai-hua, DENG Shi-gui, WU Zhi-feng, OU Run-mei. Tissue distribution of adriamycin-loaded chitosan nanoparticles surface-modified with glycyrrhizin in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(1): 66-71.
[14]	HUANG Xiu-wang, XU Jian-hua, CHEN Yuan-zhong. Tissue distribution of triptolide in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(7): 764-767.
[15]	LI Juan, ZHANG Yan, WANG Guang-ji. Pharmacokinetics and in vitro-in vivo correlation evaluation of selfemulsifying drug delivery system and conventional tablets of aniracetam [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(4): 434-439.